Kimberly-Clark Corporation

🇺🇸New York Stock Exchange
Back to all articles
Kimberly-Clark Corporation stock analysis KMB overview
Slightly Bullish +25

Kimberly-Clark vs. The Clorox: Which Consumer Goods Stock Is a Better Buy in 2026?

📊 Kimberly-Clark (KMB) holds dominant market share in personal care with brands like Huggies and Kleenex, while Clorox (CLX) leads in household cleaning and bleach categories.

📉 KMB reported FY 2025 revenue of $16.4 billion, a decline from the prior year, alongside net income dropping to $2.0 billion from $2.5 billion in 2024.

💰 Clorox generated $7.1 billion in revenue for FY 2025 with flat growth but saw net income surge to $810 million from $280 million due to profitability recovery.

🏢 KMB has a debt-to-equity ratio of 4.8x and a current ratio of 0.7x, whereas Clorox shows higher leverage at 9.0x debt-to-equity and a 0.8x current ratio.

🛒 Both companies face customer concentration risk, with Walmart accounting for roughly 16% of KMB's sales and nearly 27% of Clorox's net sales in FY 2025.

📉 KMB trades at a Forward P/E of 13.2x compared to Clorox's 17.4x, making the former appear more affordable relative to future earnings estimates.

🌍 KMB faces operational risks from geopolitical instability affecting half its international sales and intense competition requiring significant advertising spend.

💻 Clorox is recovering from a major 2023 cyberattack and growth slowdown, with margins trending back toward pre-cyberattack levels despite high debt.

🔄 KMB is executing a strategic shift by selling 51% of its international tissue business to Suzano to streamline global operations and reduce factory management.

💼 KMB announced a potential $48 billion merger with Kenvue, which would create a personal care juggernaut but significantly increase the company's debt load.

📉 Clorox trades at a P/S ratio of 1.7x, near a decade-long low and well below its 10-year average of 2.9x, suggesting potential undervaluation.

🏆 Clorox generates 80% of its sales from brands ranked No. 1 or No. 2 in their respective niches, offering historical stability aside from recent disruptions.

⚠️ The Motley Fool analyst team did not include Kimberly-Clark in their top 10 stock list for investors to buy now as of May 28, 2026.

📈 KMB offers higher outperformance potential with elevated risk due to pending deals and integration complexities compared to the safer Clorox option.

🏭 KMB's primary customers are large retailers, adding a layer of business risk that investors must weigh against its essential product portfolio.

🔒 Cybersecurity remains a significant concern for Clorox following the 2023 incident, alongside risks from executing a large-scale software upgrade.

📉 Both companies are currently in full-blown turnaround mode, navigating shifting consumer demand and high commodity costs in the consumer staples sector.

💡 Investors must consider that KMB's potential merger with Kenvue could alter its financial profile significantly before making a buy decision.

📊 Clorox's net margin of 11.4% reflects improved profitability after recovering from previous periods of lower earnings performance.

🌐 The broader SPDR XLP sector ETF benchmark shows higher multiples, with KMB and Clorox both trading at lower valuations than the sector average.

Bullish Signals
  • Kimberly-Clark maintains a dominant global presence with essential personal care brands like Huggies and Kleenex.
  • The company generated nearly $1.6 billion in free cash flow, providing capital for dividends or reinvestment.
  • Kimberly-Clark is selling 51% of its international tissue business to Suzano to streamline operations and reduce complexity.
  • A massive potential merger with Kenvue could create a personal care juggernaut, offering significant upside potential.
  • Kimberly-Clark trades at a Forward P/E of 13.2x, which is more affordable than The Clorox Company's 17.4x and well below the sector benchmark of 25.5x.
  • The company produces essential personal care and family care products under recognizable brands including Huggies, Kleenex, Poise, and Cottonelle.
Risk Factors
  • Kimberly-Clark reported revenue of nearly $16.4 billion in FY 2025, down from $16.8 billion the prior year.
  • Net income declined to approximately $2.0 billion from $2.5 billion in the prior fiscal period.
  • The company has a debt-to-equity ratio of nearly 4.8x and a current ratio of roughly 0.7x, indicating elevated leverage and liquidity pressure.
  • Walmart accounts for approximately 16% of its net sales from continuing operations, creating customer concentration risk where large retailers can demand lower pricing or prioritize private-label products.
  • Kimberly-Clark faces intense competition from Procter & Gamble and generic store brands, requiring significant spending on advertising and innovation to maintain market share.
  • Geopolitical instability and currency fluctuations affect half of its sales outside the United States, complicating operational risks.
  • The company is selling 51% of its international tissue business to Suzano, reducing from managing 22 factories with operations in over 70 countries to licensing brands, which introduces integration and execution risk.
  • A massive $48 billion potential merger with Kenvue would increase the debt load and create significant integration risks for shareholders.
  • The Motley Fool Stock Advisor analyst team identified Kimberly-Clark as not being among their 10 best stocks for investors to buy now.
Full Analysis
Kimberly-Clark (KMB) maintains a dominant global presence with essential personal care brands like Huggies and Kleenex, while The Clorox Company holds a strong market share in household cleaning and bleach categories. In FY 2025, Kimberly-Clark reported revenue of nearly $16.4 billion, down from $16.8 billion the prior year, with net income declining to approximately $2.0 billion from $2.5 billion, resulting in a net margin of 12.2%. The company has a debt-to-equity ratio of nearly 4.8x and a current ratio of roughly 0.7x, with free cash flow totaling nearly $1.6 billion. Walmart accounts for approximately 16% of its net sales from continuing operations. The Clorox Company generated nearly $7.1 billion in revenue for FY 2025, essentially flat compared to the previous year, with net income rising significantly to approximately $810.0 million from $280.0 million in 2024, leading to a net margin of roughly 11.4%. Clorox has a debt-to-equity ratio of approximately 9.0x and a current ratio of roughly 0.8x, with free cash flow totaling nearly $761.0 million. Walmart and its affiliates accounted for nearly 27% of Clorox's net sales in FY 2025. Kimberly-Clark faces intense competition from Procter & Gamble and generic store brands, requiring significant spending on advertising and innovation to maintain market share. Geopolitical instability and currency fluctuations affect half of its sales outside the United States. Clorox faces significant customer concentration risk with Walmart accounting for nearly 27% of net sales, giving large retailers power to demand lower pricing or prioritize private-label products. Cybersecurity remains a concern following a major 2023 incident, alongside execution risks associated with a large-scale software upgrade. Kimberly-Clark appears more affordable based on its Forward P/E of 13.2x relative to future earnings estimates compared to Clorox's 17.4x and the sector benchmark of 25.5x. Kimberly-Clark is selling 51% of its international tissue business to Suzano to streamline operations, reducing from managing 22 factories with operations in over 70 countries to licensing brands to the Brazilian-based pulp manufacturer. The company also announced a massive $48 billion potential merger with Kenvue, which would create a personal care juggernaut but increase debt load and integration risks. Clorox is in a turnaround following a growth slowdown after its pandemic-aided boost and a massive 2023 cyberattack it is still recovering from financially, with margins gradually trending back to pre-cyberattack and pre-pandemic levels.